Mariko Sato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mariko Sato has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ai Izumika
Department of Medical Oncology, Nagoya Medical Center, 4-1-1 Sannomaru, Naka-Ku, Nagoya 460-0001, Japan
1 shared publication - Akari Iwakoshi
Department of Pathology National Hospital Organization Nagoya Medical Center Nagoya Aichi Japan
1 shared publication - Chiyoe Kitagawa
Department of Medical Oncology, NHO Nagoya Medical Center, Nagoya, Aichi, Japan
1 shared publication - Hiroyoshi Hattori
Department of Clinical Genetics, National Hospital Organization Nagoya Medical Center, Aichi, Japan
1 shared publication - Kazuhiro Shiraishi
Department of Medical Oncology, Nagoya Medical Center, 4-1-1 Sannomaru, Naka-Ku, Nagoya 460-0001, Japan
1 shared publication - Keiji Sugiyama
Department of Medical Oncology, NHO Nagoya Medical Center, Nagoya, Japan
1 shared publication
Latest Publications
- Open Access
- 21 May 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (3) , 1938-1945
Successful Alectinib Treatment for Carcinoma of Unknown Primary with EML4-ALK Fusion Gene: A Case Report
Gene alteration in anaplastic lymphoma kinase (ALK) is rare, and the efficacy of ALK inhibitors in the treatment of carcinoma of unknown primary (CUP) with ALK alteration remains unclear. The patient was a 56-year-old woman who presented with cervical lymph node swelling. Computed tomography revealed paraaortic, perigastric, and cervical lymph node swelling; ascites; a liver lesion; and a left adrenal mass. A cervical lymph node biopsy was performed, and pathological diagnosis of an undifferentiated malignant tumor was conducted. Finally, the patient was diagnosed with CUP and treated with chemotherapy. To evaluate actionable mutations, we performed a multigene analysis, using a next-generation sequencer (FoundationOne® CDx). It revealed that the tumor harbored an echinoderm microtubule-associated protein-like 4 (EML4) and ALK fusion gene. Additionally, immunohistochemistry confirmed ALK protein expression. Alectinib, a potent ALK inhibitor, was recommended for the patient at a molecular oncology conference at our institution. Accordingly, alectinib (600 mg/day) was administered, and the multiple lesions and symptoms rapidly diminished without apparent toxicity. The administration of alectinib continued for a period of 10 months without disease progression. Thus, ALK-tyrosine kinase inhibitors should be considered in patients with CUP harboring the EML4-ALK fusion gene.
- 21 May 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (3) , 1938-1945
Open AccessSuccessful Alectinib Treatment for Carcinoma of Unknown Primary with EML4-ALK Fusion Gene: A Case Report
Gene alteration in anaplastic lymphoma kinase (ALK) is rare, and the efficacy of ALK inhibitors in the treatment of carcinoma of unknown primary (CUP) with ALK alteration remains unclear. The patient was a 56-year-old woman who presented with cervical lymph node swelling. Computed tomography revealed paraaortic, perigastric, and cervical lymph node swelling; ascites; a liver lesion; and a left adrenal mass. A cervical lymph node biopsy was performed, and pathological diagnosis of an undifferentiated malignant tumor was conducted. Finally, the patient was diagnosed with CUP and treated with chemotherapy. To evaluate actionable mutations, we performed a multigene analysis, using a next-generation sequencer (FoundationOne® CDx). It revealed that the tumor harbored an echinoderm microtubule-associated protein-like 4 (EML4) and ALK fusion gene. Additionally, immunohistochemistry confirmed ALK protein expression. Alectinib, a potent ALK inhibitor, was recommended for the patient at a molecular oncology conference at our institution. Accordingly, alectinib (600 mg/day) was administered, and the multiple lesions and symptoms rapidly diminished without apparent toxicity. The administration of alectinib continued for a period of 10 months without disease progression. Thus, ALK-tyrosine kinase inhibitors should be considered in patients with CUP harboring the EML4-ALK fusion gene.